Core Insights - Obesity is a chronic and relapsing disease affecting nearly 2 billion adults globally, increasing the risk of other chronic diseases and premature death [1][9] - The emergence of GLP-1 receptor agonists and GLP-1/GIP dual agonists is seen as a transformative approach to obesity treatment, offering significant weight loss and cardiovascular protection [1][9] - A recent systematic review and meta-analysis published in the BMJ highlights the common issue of weight regain after cessation of these medications, emphasizing the need for understanding this rebound for long-term management [9][14] Study Overview - The analysis included 37 studies with 9,341 participants and an average follow-up of 32 weeks, focusing on weight management medications compared to non-pharmacological interventions or placebos [9][10] - Among the studies, 35 were randomized controlled trials, but only 28 had control groups during both intervention and follow-up periods [10] Weight Loss and Rebound - The average weight loss during treatment across all medication groups was 8.3 kg, compared to 3.2 kg in control groups [11] - GLP-1 receptor agonists achieved an average weight loss of 10.1 kg, while newer agents like semaglutide and tirzepatide reached 14.7 kg [11] - Post-medication, the average weight regain rate was 0.4 kg/month, with a return to baseline weight expected in 1.7 years [11][14] Cardiovascular and Metabolic Indicators - During treatment, HbA1c decreased by 0.9 mmol/mol, with a monthly increase of 0.05 mmol/mol post-treatment [13] - Other indicators such as fasting blood glucose, systolic blood pressure, and cholesterol levels also showed significant reductions during treatment, but began to rise again after cessation [13] Comparison with Behavioral Interventions - Behavioral interventions resulted in an average weight loss of 5.1 kg, with a slower rebound rate of 0.1 kg/month, taking approximately 3.9 years to return to baseline [7][14] - Sensitivity analyses indicated that the rebound rate for medication groups was consistently faster than for behavioral interventions, regardless of initial weight loss [7][14] Conclusion and Future Directions - The findings suggest that while weight loss medications are effective, their benefits diminish after discontinuation, necessitating long-term management strategies [14] - The commentary accompanying the study stresses that GLP-1 receptor agonists should not be viewed as a "magic bullet" for obesity, highlighting the importance of a healthy diet and lifestyle as foundational elements of obesity management [14]

整理 | GLP1减重宝典内容团队 司美格鲁肽，这一因"显著减重效果"而广受关注的GLP-1类药物，近日迎来重要进展。其口服片剂正式获得美国食品药品监督管理局批 准用于体重管理。此前，司美格鲁肽注射剂已作为全球首个GLP-1类减重药物获批使用，并于去年在我国获准用于成人体重控制。此次 口服剂型的获批，再度点燃公众对"更轻松减重"的期待。 但减重真的只是"吃一片药"这么简单吗？ 版权声明：所有「GLP1减重宝典」的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则减重宝典将向其追究法律责 任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题，敬请原作者联系我们。合作事宜，请添加微信：andyxu365 从作用机制来看，司美格鲁肽并非通过直接"燃脂"实现体重下降。GLP-1是一种参与血糖与能量代谢调节的肠促胰岛素类激素，司美格 鲁肽作为其类似物，能够激活胰岛β细胞以及胃肠道和中枢神经系统相关受体，促进胰岛素分泌、抑制胰高血糖素释放，同时延缓胃排 空、通过中枢神经通路抑制食欲。其核心效果在于降低饥饿感、减少进食欲望，并延长餐后饱腹时间，从而自然减少能量摄入。 口服版与注射版在药理机 ...

Core Viewpoint - The oral version of semaglutide, a "star drug" for weight loss, has been approved by the U.S. FDA, following the approval of its injectable form as the world's first GLP-1 class weight loss medication, sparking public interest in convenient weight loss solutions [1] Group 1: Mechanism of Action - GLP-1 (glucagon-like peptide-1) regulates insulin and glucagon secretion based on blood sugar levels, and semaglutide is a similar compound that activates receptors in various cells to promote insulin secretion, suppress glucagon, and delay gastric emptying, thereby reducing appetite [2] - The core mechanism of semaglutide for weight loss is not fat burning but rather activating neural circuits related to satiety in the hypothalamus and brainstem, leading to reduced hunger and delayed feelings of hunger after meals [2] Group 2: Drug Comparison and Usage - The oral and injectable forms of semaglutide share the same active ingredients and mechanisms, with the oral form being more convenient but requiring higher doses due to lower bioavailability [3] - Current weight loss prescription drugs in China primarily consist of GLP-1 class medications, with BMI (Body Mass Index) being a key criterion for usage; individuals with a BMI of 28 or higher, or 24 with obesity-related complications, may be prescribed these medications [4] - Other weight loss medications include orlistat, which is the only over-the-counter option, but it has poor tolerance and more side effects; new generation dual-target and triple-target weight loss drugs are under development [4] Group 3: Risks of Misuse - The convenience of the oral version raises concerns about potential drug misuse, particularly among individuals not meeting the criteria for its use, which could lead to negative health outcomes such as muscle loss, nutritional deficiencies, and increased risks of gallstones and thyroid tumors [5] - Lifestyle interventions remain essential for effective weight management, and the public should not rely solely on medications for rapid weight loss, as there is a risk of rebound weight gain after discontinuation [6]

Core Viewpoint - The American College of Cardiology (ACC) has officially recognized semaglutide and tirzepatide as preferred medications for obesity treatment, marking a significant shift in the management of obesity and its associated cardiovascular risks [7][10]. Summary by Sections Breakthrough Therapies - Innovative drugs like semaglutide and tirzepatide not only significantly reduce weight but also provide additional cardiovascular protection for high-risk patients, particularly those with type 2 diabetes or existing cardiovascular diseases [10]. Obesity as a Health Threat - Obesity is highlighted as a serious health risk, leading to metabolic disorders, respiratory issues, and various heart diseases. It is recognized as an independent risk factor for cardiovascular diseases [11]. Weight Loss Thresholds - Different weight loss percentages yield varying cardiovascular benefits: a 10%-15% weight loss can reduce general cardiovascular risks, while heart failure patients may need to lose over 15% for significant improvement [12]. Treatment Options - The treatment landscape includes lifestyle interventions, weight loss surgery, and pharmacotherapy. The ACC suggests a reevaluation of the traditional approach of prioritizing lifestyle changes before medication [15]. Third-Generation Weight Loss Drugs - Semaglutide and tirzepatide represent a revolutionary choice in obesity management, with long-term efficacy and safety data supporting their use for weight loss [16]. Weight Loss Effectiveness - Comparative data shows that semaglutide leads to an average weight loss of 14.9%, while tirzepatide achieves an average of 20.9%, making it the most effective option currently available [18][20]. Long-Term Treatment Importance - Long-term treatment is crucial as stopping medication can lead to weight regain. Continuous use combined with lifestyle adjustments is essential for maintaining weight loss [21]. Accessibility and Economic Burden - The main challenges for semaglutide and tirzepatide include limited supply and high costs, which may affect patient access to these therapies [22]. Cardiovascular Benefits Beyond Weight Loss - The NuSH therapy not only aids in weight loss but also reduces the risk of heart attacks and strokes in obese patients without diabetes, and improves outcomes for heart failure patients [23]. Approved Weight Loss Medications in China - The 2024 guidelines in China have approved five medications for adult weight loss, emphasizing a multidisciplinary approach to obesity treatment [24].

Core Viewpoint - The article discusses a systematic review and network meta-analysis published in The Lancet, which evaluates the effectiveness and safety of seven weight loss medications for overweight and obese adults, highlighting that the combination of phentermine-topiramate and GLP-1 receptor agonists, particularly semaglutide, show the most significant weight loss effects [5][19]. Research Methodology - The research team systematically searched three major databases: PubMed, Embase, and Cochrane Library, including randomized controlled trials (RCTs) published until March 23, 2021, focusing on weight loss medications for overweight and obese adults [7]. - Exclusion criteria included studies with a crossover design, combination of multiple medications, participants with psychological disorders, pregnant women, normal weight individuals, and non-English publications [7]. Study Results - A total of 14,605 articles were screened, resulting in 132 studies included, with 48,209 participants. The median age of participants was 47 years, with a female proportion of 76% and a median BMI of 35.3 kg/m² [11]. - The study assessed the impact of seven medications on six outcome measures, including weight loss percentage, proportion of participants achieving 5% or 10% weight loss, quality of life improvement, reduction in depressive symptoms, and safety indicators [10]. Comparative Effectiveness - Compared to lifestyle modifications alone, all weight loss medications resulted in additional weight loss. Phentermine-topiramate showed the most significant weight loss effect, with an odds ratio (OR) of 8.02 for achieving a weight reduction of ≥5% and an average weight loss percentage of -7.98% [17]. - GLP-1 receptor agonists also demonstrated significant effects, with an OR of 6.33 for achieving a weight reduction of ≥5% and an average weight loss percentage of -5.79% [17]. Specific Drug Analysis - Among GLP-1 receptor agonists, semaglutide exhibited the most pronounced weight loss effects, with an OR of 9.82 for achieving a weight reduction of ≥5% and an average weight loss percentage of -11.40% [18]. - Safety data indicated that medications like naltrexone-bupropion, phentermine-topiramate, GLP-1 receptor agonists, and orlistat were associated with an increased risk of discontinuation due to adverse events [18]. Conclusion - The network meta-analysis provides high to moderate confidence evidence that phentermine-topiramate and GLP-1 receptor agonists, especially semaglutide, are the most effective weight loss medications, with average weight reductions ranging from 6% to 11% [19].

Core Viewpoint - The article discusses the rising obesity rates in China, highlighting the need for effective weight management strategies and the increasing popularity of specialized weight loss clinics that offer comprehensive treatment plans [5][12][20]. Group 1: Obesity Statistics and Causes - According to the National Health Commission, the overweight rate in China is 34.3% and the obesity rate is 16.4%, indicating that over 700 million people are facing weight issues [5]. - Factors contributing to obesity include lifestyle pressures, unregulated diets, and mental health challenges, leading to the emergence of various weight loss methods [5][12]. Group 2: Weight Management Clinics - The year has been designated as the "Weight Management Year," prompting a surge in young people visiting nutrition clinics for professional weight loss advice [5][12]. - Modern medical approaches provide tailored weight loss plans, including dietary recommendations, exercise suggestions, and, when necessary, medication or surgery [5][12]. Group 3: Patient Experiences - Case studies of individuals like Ouyang and Manxiao illustrate the emotional and physical struggles associated with obesity, as well as their journeys through weight loss clinics [7][15]. - Patients undergo comprehensive assessments, including questionnaires about eating habits and physical conditions, to receive personalized treatment plans [9][11]. Group 4: Treatment Approaches - The treatment strategies involve lifestyle interventions, such as dietary adjustments and exercise regimens, with some patients opting for medication like GLP-1 receptor agonists under medical supervision [20][22]. - The article emphasizes that obesity is a chronic disease requiring a systematic approach, including lifestyle changes, medication, and possibly surgical options for severe cases [15][20]. Group 5: Long-term Management - Patients are encouraged to view weight management as a lifelong commitment, focusing on sustainable lifestyle changes rather than quick fixes [24]. - The experiences shared highlight the importance of professional guidance in navigating the complexities of weight loss and maintaining a healthy lifestyle [24].

Core Viewpoint - The article discusses a systematic review and network meta-analysis published in The Lancet, which evaluates the weight loss effects and safety of seven medications for overweight and obese adults, highlighting that the combination of phentermine-topiramate and GLP-1 receptor agonists, particularly semaglutide, show the most significant weight loss potential [5][19]. Research Methodology - The research team systematically searched three major databases: PubMed, Embase, and Cochrane Library, including randomized controlled trials (RCTs) published until March 23, 2021, focusing on weight loss medications for overweight and obese adults [7]. - Exclusion criteria included studies with a crossover design, those using multiple medications, participants with psychological disorders, pregnant women, normal-weight individuals, and non-English publications [7]. Study Results - A total of 14,605 articles were screened, resulting in 132 studies included, with 48,209 participants. The median age of participants was 47 years, with a female proportion of 76% and a median BMI of 35.3 kg/m² [11]. - The study assessed the impact of seven medications on six outcome measures, including weight loss percentage, proportion of participants achieving 5% or 10% weight loss, quality of life improvement, reduction in depressive symptoms, and safety indicators [10]. Comparative Effectiveness - Compared to lifestyle modifications alone, all weight loss medications provided additional weight reduction. Phentermine-topiramate showed the most significant effect, with an odds ratio (OR) of 8.02 for achieving a weight loss of ≥5% and an average weight reduction of -7.98% [17]. - GLP-1 receptor agonists also demonstrated substantial effects, with an OR of 6.33 for achieving a weight loss of ≥5% and an average weight reduction of -5.79% [17]. Specific Drug Analysis - Among GLP-1 receptor agonists, semaglutide exhibited the most pronounced weight loss effects, with an OR of 9.82 for achieving a weight loss of ≥5% and an average weight reduction of -11.40% [18]. - Safety data indicated that medications like naltrexone-bupropion, phentermine-topiramate, GLP-1 receptor agonists, and orlistat were associated with an increased risk of discontinuation due to adverse events [18]. Conclusion - The network meta-analysis provides high to moderate confidence evidence that phentermine-topiramate and GLP-1 receptor agonists, especially semaglutide, are the most effective weight loss medications, with average weight reductions ranging from 6% to 11% [19].

Core Viewpoint - The article discusses the current landscape of weight loss medications in China, focusing on the differences between new-generation GLP-1 drugs and traditional weight loss medications, highlighting their mechanisms, efficacy, and safety profiles [4][7]. Group 1: Overview of Weight Loss Medications - There are six weight loss drugs currently approved in China, including three new-generation GLP-1 drugs: Semaglutide, Tirzepatide, and Mounjaro, and three traditional drugs: Benaglutide, Liraglutide, and Orlistat [4][7]. - New-generation GLP-1 drugs have longer action times and more significant weight loss effects compared to first-generation drugs [4][6]. Group 2: Mechanisms and Administration - The six weight loss drugs differ in their mechanisms of action and target populations, with new-generation drugs showing better safety and efficacy [7]. - All approved GLP-1 weight loss medications are currently available only as subcutaneous injections, with no oral versions available yet [6]. Group 3: Indications and Contraindications - Weight loss medications should be considered for patients who have not achieved a weight loss of at least 5% after three months of lifestyle intervention, even for those who are merely overweight without complications [9]. - A comprehensive assessment is necessary before starting medication, especially for high-risk populations such as the elderly or those with liver and kidney dysfunction [10]. Group 4: Clinical Application Process - Diagnosis of obesity or overweight should consider BMI, metabolic indicators, and related comorbidities, with obesity defined as BMI ≥ 28 kg/m² [12]. - The selection of medications should prioritize those with additional clinical benefits for patients with comorbid conditions like type 2 diabetes or cardiovascular diseases [13]. Group 5: Monitoring and Management - Regular monitoring of body composition and metabolic indicators is essential, with evaluations occurring monthly during the initial three months and quarterly thereafter [16]. - For elderly patients, careful consideration of muscle mass and potential drug interactions is crucial, with recommendations for dose adjustments based on renal and hepatic function [19].

Core Viewpoint - The American College of Cardiology (ACC) has officially recognized semaglutide and tirzepatide as preferred medications for obesity treatment, marking a significant shift in obesity management strategies [4][7]. Group 1: Breakthrough Therapies - Innovative drugs like semaglutide and tirzepatide not only significantly reduce weight but also provide additional cardiovascular protection for high-risk patients, effectively lowering the risks of cardiovascular death, heart attacks, and strokes [10]. - These medications represent the most effective weight loss solutions currently available, particularly for patients with type 2 diabetes or existing cardiovascular diseases [10]. Group 2: Obesity as a Health Threat - Obesity is highlighted as a critical health risk, contributing to metabolic disorders, respiratory issues, and various heart diseases, and is recognized as an independent risk factor for cardiovascular diseases [11]. - The consensus emphasizes that obesity is not merely an aesthetic issue but a serious health concern that requires urgent attention [11]. Group 3: Weight Loss Thresholds - Research indicates that different degrees of weight loss yield varying cardiovascular benefits: a 10%-15% weight loss can reduce general cardiovascular risks, while heart failure patients may need to lose over 15% for significant improvements [12]. - The treatment options include lifestyle interventions, weight loss surgery, and pharmacotherapy, with the latter being increasingly favored due to its effectiveness and safety [12][13]. Group 4: NuSH Therapy Advantages - NuSH therapy, which includes semaglutide and tirzepatide, is praised for its unique advantages, including targeting appetite regulation and allowing for personalized dosage adjustments to achieve optimal results [19]. - The therapy is seen as a pivotal advancement in obesity treatment, ushering in an era of precision medicine [13]. Group 5: Comparison of Weight Loss Medications - Semaglutide (weekly) leads to an average weight loss of 14.9%, while tirzepatide (weekly) shows the highest efficacy with an average weight loss of 20.9% [18][20]. - Other medications like liraglutide (daily) result in an average weight loss of 8% [18]. Group 6: Long-term Treatment and Challenges - Long-term treatment is crucial, as discontinuation can lead to weight regain; thus, a combination of medication and lifestyle changes is essential for maintaining weight loss [21]. - Current challenges include limited availability and high costs of semaglutide and tirzepatide, which may hinder accessibility for patients [22]. Group 7: Cardiovascular Benefits Beyond Weight Loss - The benefits of NuSH therapy extend beyond weight reduction, with semaglutide reducing the risk of heart attacks and strokes in non-diabetic obese patients, and improving exercise capacity in heart failure patients [23]. - Treatment goals should be individualized, focusing on weight loss of at least 5% to improve metabolic health and 10% for cardiovascular benefits [23].

Financial Performance - The company repaid all acquisition loans to AVIC Trust amounting to 830 million yuan using self-owned and self-raised funds [1] - For the first half of 2025, the company achieved a total revenue of 179.79 million yuan [2] - The company aims to ensure the completion of its annual operational goals and mitigate delisting risks [3] Employee Information - As of December 31, 2024, the total number of employees is 383, excluding the subsidiary Ruien Pharmaceutical [2] Restructuring Plans - The company is currently in the pre-restructuring phase, with the Chongqing Fifth Intermediate People's Court completing the filing for pre-restructuring [3] - There is significant uncertainty regarding whether the company will formally enter the restructuring process [3] - The company signed restructuring investment agreements with strategic investors in September 2025, which may lead to changes in control [3][4] Debt and Compensation - The company is actively pursuing the collection of performance compensation from individuals, with a total of 135 million yuan already paid by Kou Han and 21.41 million yuan by Lin Jiaxi, leaving outstanding balances of 311.99 million yuan and 22.70 million yuan respectively [5][6] - The company is conducting a debt review as part of the pre-restructuring process, with specific figures to be disclosed in future announcements [5] Future Outlook - The company is focused on improving its core business operations and exploring partnerships to enhance market demand [8] - The introduction of strategic investors is expected to provide financial and operational support to improve the company's performance [9][10] - The company plans to implement a capital increase through the conversion of capital reserves, with a proposed ratio of 10 shares for every 4.8 shares issued [13][14]